Nuvation gets in before Nuvalent
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
Akeso looks early in small-cell lung cancer
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
Avenzo takes a second shot at CDK-selective inhibition
AVZO-023 follows AVZO-021 into clinical trials.
AbbVie's telisotuzumab conjugate take two
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
Kura joins the pivotal menin push
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
A bispecific encore, plus two in vivo Cars
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
ASCO 2025 movers – bispecifics to the rescue
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Werner not good enough for Roche
Roche dumps another partnered asset.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
